Unicycive Therapeutics (UNCY) Q4 2024 earnings summary

Executive summary

• NDA for oxylanthanum carbonate (OLC) for hyperphosphatemia in CKD patients on dialysis under FDA review, with a PDUFA date of June 28, 2025.

• Commercial launch preparations for OLC underway, targeting late 2025.

• OLC NDA also submitted in Korea via Lotus Pharmaceutical, with a decision expected in June 2026 and potential milestone/royalty payments.

• Expanded awareness of OLC through publications and presentations, highlighting efficacy, safety, and bioequivalence to approved therapies.

• Successfully completed Phase 1 study of UNI-494, demonstrating favorable tolerability and rapid metabolization.

Financial highlights

• Licensing revenues decreased by $0.7 million year-over-year due to a prior period upfront payment; no comparable revenue in 2024.

• R&D expenses rose to $20.0 million for 2024 from $12.9 million in 2023, driven by increased drug development and labor costs.

• G&A expenses increased to $12.1 million from $8.5 million year-over-year, mainly due to higher labor, consulting, and professional services.

• Other income fell to $4.6 million from $9.8 million, primarily due to a decrease in the fair value of warrant liability.

• Net loss attributable to common stockholders widened to $37.8 million ($0.56/share) from $31.4 million ($1.28/share) year-over-year.

• Cash and cash equivalents totaled $26.1 million as of December 31, 2024.

Outlook and guidance

• Sufficient resources to fund planned operations into 2026.

• Anticipated FDA approval and commercial launch of OLC in late 2025.

• Potential for additional milestone and royalty payments from international partnerships.